跳至主要内容
临床试验/NCT01248637
NCT01248637已完成不适用

A Clinical Trial of Intratumoral Hypoxia and Its Biologic Correlates in Patients Undergoing Surgical Resection of Localized Pancreatic Cancer, Using Pre-operative Administration of the Hypoxia Marker Pimonidazole.

University Health Network, Toronto1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2010年10月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
200
试验地点
1
主要终点
characterization of intratumoral hypoxia in pancreatic cancer

研究概览

简要总结

This study involves the administration of a hypoxia marker, pimonidazole hydrochloride, taken orally approximately 24 hours before surgical resection of a pancreatic tumor in order to identify areas of lower oxygen content on tumor samples.

详细描述

Intratumoral hypoxia (low oxygen concentration or pO2) occurs when oxygen consumption exceeds its delivery by the vascular system. Hypoxia is associated with adverse patient outcome in many human cancers and this association is hypothesized to be due to a combination of treatment resistance and aggressive tumor biology.

The study of hypoxia is also important as new cancer drugs are being developed that are specifically active on cancer cells in area of tumors with lower oxygen levels.

his study involves administering the hypoxia probe pimonidazole hydrochloride to patients prior to resection of pancreatic adenocarcinoma to evaluate the extent, molecular context and clinical relevance of hypoxia in clinical pancreatic cancer samples and the subsequently derived primary xenograft tumors.

We propose accrual of patients over a 5-year period to evaluate hypoxia within 100 clinical tumor specimens and corresponding primary xenograft tumours where available. The complementary techniques of wide-field multicolor fluorescence image analysis microscopy and high level flow cytometry will be used to identify potential relationships between intratumoral hypoxia and cell proliferation, differentiation, and the expression of putative cancer stem cell markers.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Other

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • age > 18
  • provisional diagnosis of pancreatic cancer
  • scheduled resection at UHN
  • consented to ICGC Pancreatic Cancer Genome Project
  • surgery planned for >2 days away (drug administration has to be 16-20hrs before surgery)

排除标准

  • not participating in ICGC
  • contraindications to pimonidazole (allergy)
  • surgery scheduled for same or next day (not enough time to arrange for drug administration)

研究组 & 干预措施

Pimonidazole hydrochloride

Oral pimonidazole is administered at a dose of 0.5gm/m2 once approximately 24 hrs prior to surgery

干预措施: Pimonidazole hydrochloride (Drug)

结局指标

主要结局

characterization of intratumoral hypoxia in pancreatic cancer

时间窗: 5 Years

estimation of tumoral hypoxic fraction by immunodetection of pimonidazole adducts.

correlation of intratumoral hypoxia with patient survival rate

时间窗: 5 Years

evaluation of correlation of tumoral hypoxia with disease-free survival using Cox proportional hazards analysis

次要结局

  • to assess utility of circulating osteopontin and miR-210 for identifying hypoxia(5 Years)
  • correlation of hypoxia with molecular markers(5 Years)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验